Grape Seed Proanthocyanidin Extract Ameliorates Streptozotocin-induced Cognitive and Synaptic Plasticity Deficits by Inhibiting Oxidative Stress and Preserving AKT and ERK Activities

• Published in: Current medical science 2020-06, Vol.40 (3), p.434-443
• Main Authors: Gao, Wei-li, Li, Xiang-hua, Dun, Xin-peng, Jing, Xiao-kuan, Yang, Ke, Li, Yan-kun
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - chemically induced; Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Animals; Antioxidants - physiology; Cognition - drug effects; Cognitive Dysfunction - drug therapy; Cognitive Dysfunction - metabolism; Disease Models, Animal; Glutathione - metabolism; Grape Seed Extract - pharmacology; Hippocampus - drug effects; Hippocampus - metabolism; Long-Term Potentiation - drug effects; Male; Malondialdehyde - metabolism; MAP Kinase Signaling System - drug effects; Maze Learning - drug effects; Medicine; Medicine & Public Health; Memory - drug effects; Neuronal Plasticity - drug effects; Oxidative Stress - drug effects; Proanthocyanidins - pharmacology; Proto-Oncogene Proteins c-akt - metabolism; Rats; Rats, Sprague-Dawley; Streptozocin - pharmacology; Superoxide Dismutase - metabolism
• ISSN: 2096-5230; 2523-899X
• DOI: 10.1007/s11596-020-2197-x

Summary Progressive memory loss and cognitive impairment are the main clinical manifestations of Alzheimer’s disease (AD). Currently, there is no effective drug available for the treatment of AD. Previous studies have demonstrated that the cognitive impairment of AD is associated with oxidative stress and the inhibition of AKT and ERK phosphorylation. Grape seed proanthocyanidin extract (GSPE) has been shown to have strong antioxidant effect and can protect the nervous system from oxidative stress damage. This study aimed to investigate the protective effect of GSPE on the cognitive and synaptic impairments of AD using a sporadic AD rat model induced by intracerebroventricular (ICV) injection of streptozotocin (STZ) (ICV-STZ). Rats were treated with GSPE (50, 100, or 200 mg/kg every day) by intragastrical (ig.) administration for continuous 7 weeks, and ICV-STZ (3 mg/kg) was performed on the first day and third day of week 5. Learning and memory abilities were assessed by the Morris water maze (MWM) test at week 8. After behavioral test, hippocampal long-term potentiation (LTP) was recorded, and the levels of malondialdehyde (MDA), superoxide dismutases (SOD), glutathione (GSH) and the protein expression of AKT and ERK were measured in the hippocampus and cerebral cortex of rats. Our study revealed that ICV-STZ significantly impaired the working learning ability and hippocampal LTP of rats, significantly increased the levels of MDA, and decreased the activity of SOD and GSH in the hippocampus and cerebral cortex. In contrast, GSPE treatment prevented the impairment of cognitive function and hippocampal LTP induced by ICV-STZ, decreased the level of MDA, and increased the level of SOD and GSH. Furthermore, Western blot results showed that GSPE treatment could prevent the loss of AKT and ERK activities in the hippocampus and cerebral cortex induced by ICV-STZ. Our findings demonstrate that GSPE treatment could ameliorate the impairment of cognitive ability and hippocampal synaptic plasticity in a rat model of sporadic AD by inhibiting oxidative stress and preserving AKT and ERK activities. Therefore, GSPE may be an effective agent for the treatment of cognitive deficits associated with sporadic AD.